This article discusses the use of vagus nerve stimulation (VNS) for treating patients with treatment-resistant depression. It outlines the procedure for implanting a VNS device and the subsequent stimulation adjustments to optimize therapeutic outcomes.
Begin with a patient suffering from treatment-resistant depression, with a vagus nerve stimulation or VNS device implanted on the left vagus nerve.
Use a wand connected to a handheld computerized device to wirelessly control the implant.
Position the wand over the chest to transmit signals through the skin and activate the implant.
Initiate stimulation.
Electrical impulses from the implant stimulate the left vagus nerve, which projects to the brainstem.
The signals travel from the brainstem to other brain areas involved in mood regulation, activating neurons and triggering neurotransmitter release.
Receiving neurons detect these neurotransmitters, resulting in coordinated neuronal communication.
Over time, this enhanced signaling contributes to antidepressant effects.
Adjust the stimulation parameters to optimize therapeutic outcomes.
If uncomfortable side effects occur, place a magnet over the chest to temporarily stop the stimulation.
Monitor the long-term effectiveness of the treatment through regular follow-ups.
After evaluating for solid compliance and willingness to attend control and tuning visitations, connect the VNS wand to the handheld device and perform lead testing with a minimum of 10 seconds of 0.5 to 1 milliamp in 25-hertz stimulation. Intraoperative lead testing can be critical because serious side effects, such as bradycardia or even asystole, may occur in some patients. Place the electrodes inferior through the cardiac branches of the left vagus nerve to avoid such effects.
Commence regular VNS dosing two weeks after implantation, starting at 1.5 to three milliamps, a 500 microsecond pulse width, and 20 to 30 hertz for 30 seconds on, five minutes off, and gradually increasing the stimulation 0.25 to 0.5 milliamps per week up to two to three milliamps maximum. In cases of persistent depressive symptoms, end the dosing when a response to VNS is achieved up to a maximum of nine to 12 months.
In cases on non or partial response, instead of increasing the output milliamp current, decrease the signal frequency tuning from 30 to 20 hertz or reduce the off-time to three minutes. If transitory side effects occur, which tend to be directly associated with stimulation of the inferior recurrent laryngeal nerve, reduce the maximum milliamp tuning to no lower than 0.75 milliamps and/or change the on-off timing. If side effects do occur, the patient is able to use his own portable magnet to temporarily stop the VNS stimulation.
繁體中文
